HUP0201597A3 - Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines - Google Patents

Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines

Info

Publication number
HUP0201597A3
HUP0201597A3 HU0201597A HUP0201597A HUP0201597A3 HU P0201597 A3 HUP0201597 A3 HU P0201597A3 HU 0201597 A HU0201597 A HU 0201597A HU P0201597 A HUP0201597 A HU P0201597A HU P0201597 A3 HUP0201597 A3 HU P0201597A3
Authority
HU
Hungary
Prior art keywords
combunations
antilipemic
carnitines
hmg
coa reductase
Prior art date
Application number
HU0201597A
Other languages
Hungarian (hu)
Original Assignee
Sigma Tau Ind Farmaceutiche S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99830415A external-priority patent/EP1064943B1/en
Application filed by Sigma Tau Ind Farmaceutiche S filed Critical Sigma Tau Ind Farmaceutiche S
Publication of HUP0201597A2 publication Critical patent/HUP0201597A2/en
Publication of HUP0201597A3 publication Critical patent/HUP0201597A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0201597A 1999-06-08 2000-06-05 Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines HUP0201597A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13800899P 1999-06-08 1999-06-08
EP99830415A EP1064943B1 (en) 1999-06-30 1999-06-30 Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs

Publications (2)

Publication Number Publication Date
HUP0201597A2 HUP0201597A2 (en) 2002-09-28
HUP0201597A3 true HUP0201597A3 (en) 2003-04-28

Family

ID=26153794

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201597A HUP0201597A3 (en) 1999-06-08 2000-06-05 Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines

Country Status (10)

Country Link
JP (1) JP2003501385A (en)
KR (1) KR100725263B1 (en)
AU (1) AU782188B2 (en)
CA (1) CA2375378C (en)
CZ (1) CZ20014218A3 (en)
HU (1) HUP0201597A3 (en)
MX (1) MXPA01012644A (en)
PL (1) PL197899B1 (en)
SK (1) SK285900B6 (en)
WO (1) WO2000074675A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124925B1 (en) * 2007-02-27 2018-06-27 Alfasigma S.p.A. Composition useful for the treatment of type 2 diabetes
KR20090120503A (en) * 2007-03-21 2009-11-24 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
JP5677856B2 (en) * 2008-02-29 2015-02-25 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． Pharmaceutical composition
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0667833B2 (en) * 1985-11-28 1994-08-31 雪印乳業株式会社 Enteral nutrition
DE69001146T2 (en) * 1989-01-18 1993-10-07 Merck & Co Inc Coenzyme Q10 with HMG-COA reductase inhibitors.
IT1293067B1 (en) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PATHOLOGIES CAUSED BY ALTERED LIPID METABOLISM

Also Published As

Publication number Publication date
HUP0201597A2 (en) 2002-09-28
AU5969700A (en) 2000-12-28
PL352106A1 (en) 2003-07-28
SK17152001A3 (en) 2002-03-05
WO2000074675A1 (en) 2000-12-14
CA2375378C (en) 2009-08-11
MXPA01012644A (en) 2002-07-22
KR20020025066A (en) 2002-04-03
CZ20014218A3 (en) 2002-04-17
JP2003501385A (en) 2003-01-14
SK285900B6 (en) 2007-10-04
PL197899B1 (en) 2008-05-30
AU782188B2 (en) 2005-07-07
CA2375378A1 (en) 2000-12-14
KR100725263B1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
PL359820A1 (en) Hmg-coa reductase inhibitors and method
GB9900416D0 (en) Inhibitors
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
PL356066A1 (en) Caspase inhibitors and uses thereof
AU7989400A (en) Compounds and methods
AU3215500A (en) Compounds and methods
AU5991699A (en) Quinolizinones as integrin inhibitors
GB9827391D0 (en) Aldose reductase inhibitors and pharmaceutical compositions
EP1286702A4 (en) HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS
HUP0002103A3 (en) Hmg-coa reductase inhibitor preparation process
PL354979A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
AU5213300A (en) 2-nh-pyridones and pyrimidones as mrs inhibitors
AU1824201A (en) Polymorphisms in the human HMG-COA reductase gene
AU3235100A (en) Prothease inhibitors
GB9924522D0 (en) Enzyme inhibitors
AU6992500A (en) Alphavbeta3 integrin inhibitors
GB2371748B (en) HMG-COA reductase inhibitor extended release formulation
HUP0201597A2 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
AU5680900A (en) Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
GB2389113B (en) B-secretase inhibitor
AU3595900A (en) Tyrosine alkoxyguanidines as integrin inhibitors
AU7559600A (en) V type and/or x type spla2 inhibitors
AU7308300A (en) Agents for reducing cholesterol-uptake and liquid-uptake
AU3721000A (en) Corrosion inhibitor and process
HK1049666A1 (en) NOVEL INTEGRIN α V β INHIBITORS

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished